These years, more and more research has focused on how to bring potent cytotoxic substances to work on target cells as a way to explore some potential medical treatments. CD BioGlyco has developed an efficient, reliable antibody-drug conjugate (ADC) strategy to achieve Site-Specific Antibody Conjugation with PNU anthracycline. This technique helps you to conjugate your antibody of interest with PNU anthracycline to accurately release it in the target cells, helping ADC play the appropriate cytotoxic biological function. We have the confidence to become your best scenic research assistant in the field of site-specific ADC study.
ADC consists of a monoclonal antibody, a payload, and a linker connecting the first two components, it offers the possibility of accurate drug delivery. The junction of the antibody is stable in the extracellular fluid, but once the conjugate enters the target cell it is cleaved by histone proteases, which will activate the cytotoxic agent. By conjugating a selective targeting mechanism for cytotoxic drugs, site-specific ADCs can target antigens that are expressed at higher levels on target cells than normal cells, thereby killing them while reducing ground damage to other cells. Because site-specific ADCs can selectively release cytotoxic substances, efficient molecules that have been side-lined due to toxicity issues can be reconsidered, and PNU anthracycline is a strong cytotoxic substance.
Fig.1 Schematic representation of various types of ADCs and their components. (Ponziani et al., 2020)
PNU anthracycline is an anthracycline-based DNA alkylating toxin. Anthracyclines can insert into DNA and form a stable anthracycline-DNA-topoisomerase II ternary complex. DNA-topoisomerase II is associated with DNA replication, and after the formation of the ternary complex anthracyclines will cause programmed apoptosis of cells.
Fig.2 Daunorubicin, the prototypical anthracycline. (Wikipedia)
CD BioGlyco's site-specific antibody conjugation is a technology based on Fc glycan remodelling and click chemistry. We produce site-specific ADC by conjugating PNU anthracycline to antibodies such as Human IgG1-4, IgG from animals (mouse, rat, rabbit, monkey, sheep, goat, cow, and horse), and Fc-fusion proteins.
The services we provide include but are not limited to:
Unlike traditional one-step reaction-activated ADCs, CD BioGlyco's site-specific antibody conjugation service has a cleavable glycopeptide linker, which is activated by lysosomes in a two-step reaction to control drug release in target cells, it can reduce drug instability and off-target effects. We also have outstanding scientists specializing in this service.
CD BioGlyco has advanced site-specific ADC production technology, and we have the confidence to meet customers' requirements about conjugating different antibodies with PNU anthracycline. If you are interested in our services, please feel free to contact us for more detailed information.
Reference:
